I don't think Medizone as we know it will exist come 2016.
By then, lacking EPA approval, there will surely be a shareholders meeting where anything is possible and there is sure to be some sort of change.
If EPA approval is achieved, and sales are not forthcoming, the company will be marketable and a not so great deal will probably happen.
If they gain EPA approval and sales quickly follow, a much better buyout is possible.
If they gain some foreign sales this year without EPA approval it will only delay a shareholders meeting, however, it will help the share price.
In any event, I feel this is the make or break year for Medizone.
